Molecular Analysis of FLT3-Mutated Acute Myeloid Leukemia and How Clonal Changes Affect Treatment Response

What this Trial Is About

Researchers are studying patients with acute myeloid leukemia AML who have mutations in the FLT3 gene. The goal is to analyze these patients using advanced molecular techniques to identify different groups of cancer cells present at the start and observe how these groups change during treatment. This study focuses on understanding how the genetic makeup of the leukemia evolves under therapy, which may help explain why some patients do not respond well to treatment. The study uses single-cell molecular characterization methods to closely monitor the presence of cancer cell clones and subclones before and during therapy. By tracking these changes, researchers aim to detect genetic alterations that might cause resistance to FLT3 inhibitor treatments. This approach may lead to the development of new molecular markers to identify patients who are likely to be resistant or refractory to this therapy early on. Participants will be monitored to evaluate their response to therapy over time, with researchers focusing on treatment refractoriness as a primary outcome measured at the end of a three-year enrollment period. The study involves collecting and analyzing molecular data to better understand changes in the leukemia cells during treatment. This observational study is led by IRCCS Azienda Ospedaliero-Universitaria di Bologna and does not involve experimental treatments but rather detailed patient monitoring and molecular analysis.

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments